Skip to main content

Advertisement

SpringerLink
Log in

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Necrolytic migratory erythema (NME) is a classical paraneoplastic symptom observed in patients with pancreatic glucagonoma. We report a 46-year-old Japanese woman with glucagonoma who presented with mucocutaneous manifestations 1 year prior to the diagnosis of the pancreatic neoplasm with multiple liver metastases. She was treated with octreotide long-acting release, a somatostatin analog, which resulted in a dramatic improvement of NME within 2 weeks after the start of treatment. Increased awareness of NME may avoid unnecessary delay in the diagnosis of pancreatic glucagonoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.

    Article  PubMed  Google Scholar 

  2. Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594–618.

    Article  PubMed  Google Scholar 

  3. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome—cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011;74:593–8.

    Article  Google Scholar 

  4. Pujol RM, Wang CY, el-Azhary RA, Su WP, Gibson LE, Schroeter AL. Necrolytic migratory erythema: clinicopathologic study of 13 cases. Int J Dermatol. 2004;43:12–8.

    Article  PubMed  Google Scholar 

  5. Becker WSKD, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilol. 1942;45:1069–80.

    Article  Google Scholar 

  6. Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc. 1973;59:244–50.

    CAS  PubMed  Google Scholar 

  7. Soga J, Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg. 1998;5:312–9.

    Article  CAS  PubMed  Google Scholar 

  8. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75:53–63.

    Article  CAS  PubMed  Google Scholar 

  9. Nightingale KJ, Davies MG, Kingsnorth AN. Glucagonoma syndrome: survival 24 years following diagnosis. Dig Surg. 1999;16:68–71.

    Article  CAS  PubMed  Google Scholar 

  10. Bilimoria KY, Talamonti MS, Sener SF. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008;207:510–9.

    Article  PubMed  Google Scholar 

  11. Yao JC, Hassan M, Phan A. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  12. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res. 2012;18:1830–6.

    Article  CAS  PubMed  Google Scholar 

  13. Rinke A, Muller HH, Schade-Brittinger C. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

    Article  CAS  PubMed  Google Scholar 

  14. Raymond E, Dahan L, Raoul JL. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  15. Yao JC, Shah MH, Ito T. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.

    Article  CAS  PubMed  Google Scholar 

  16. Pavel ME, Hainsworth JD, Baudin E. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–12.

    Article  CAS  PubMed  Google Scholar 

  17. Rösch T, Lightdale CJ, Botet JF. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1994;326:1721–6.

    Article  Google Scholar 

Download references

Disclosures

Conflict of Interest:

All authors declare that they have no conflict of interest.

Human and Animal Rights:

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed Consent:

Informed consent was obtained from all patients for being included in the study.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan

    Shiro Kimbara

  2. Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

    Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Yoshinori Imamura, Naomi Kiyota, Toru Mukohara & Hironobu Minami

  3. Cancer Center, Kobe University Hospital, Kobe, Japan

    Toru Mukohara & Hironobu Minami

  4. Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan

    Atsushi Fukunaga, Masahiro Oka & Chikako Nishigori

  5. Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

    Yutaka Fujiwara

Authors
  1. Shiro Kimbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masanori Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoko Chayahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshinori Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naomi Kiyota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toru Mukohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsushi Fukunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiro Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chikako Nishigori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hironobu Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiro Kimbara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimbara, S., Fujiwara, Y., Toyoda, M. et al. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clin J Gastroenterol 7, 255–259 (2014). https://doi.org/10.1007/s12328-014-0471-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-014-0471-9

Keywords

Search

Navigation